Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14194653 | 0.93 | PTGS2 (0.34) | PTGS2PTGS1CDC7CDK2 | |
| SCHEMBL4808476 | 0.84 | PTGS1 (0.38) | PTGS2PTGS1L3MBTL1DGAT1CDC7 | |
| SCHEMBL4810556 | 0.80 | PTGS1 (0.37) | PTGS2PTGS1L3MBTL1DGAT1CDC7 | |
| SCHEMBL4865738 | 0.78 | PTGS2 (0.35) | PTGS2PTGS1L3MBTL1DGAT1CDC7 | |
| SCHEMBL4876991 | 0.77 | PTGS2 (0.35) | PTGS2PTGS1L3MBTL1DGAT1CDC7 | |
| SCHEMBL4859211 | 0.76 | MAPT (0.42) | PTGS2PTGS1CDC7CDK2 | |
| SCHEMBL4868771 | 0.75 | PTGS2 (0.36) | PTGS2PTGS1L3MBTL1CDC7CDK2 | |
| SCHEMBL4878202 | 0.75 | MKNK2 (0.42) | PTGS2PTGS1DGAT1 | |
| SCHEMBL4876566 | 0.75 | DGAT1 (0.36) | PTGS2PTGS1DGAT1 | |
| SCHEMBL4878495 | 0.75 | PTGS1 (0.36) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | claimed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | PTGS2 854/4885PTGS1 527/4885L3MBTL1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.